GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shenzhen Kangtai Biological Products Co Ltd (SZSE:300601) » Definitions » Capex-to-Revenue

Shenzhen Kangtai Biological Products Co (SZSE:300601) Capex-to-Revenue : 0.42 (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Shenzhen Kangtai Biological Products Co Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Shenzhen Kangtai Biological Products Co's Capital Expenditure for the three months ended in Mar. 2024 was ¥-188.71 Mil. Its Revenue for the three months ended in Mar. 2024 was ¥451.66 Mil.

Hence, Shenzhen Kangtai Biological Products Co's Capex-to-Revenue for the three months ended in Mar. 2024 was 0.42.


Shenzhen Kangtai Biological Products Co Capex-to-Revenue Historical Data

The historical data trend for Shenzhen Kangtai Biological Products Co's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhen Kangtai Biological Products Co Capex-to-Revenue Chart

Shenzhen Kangtai Biological Products Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.20 0.54 0.70 0.42 0.21

Shenzhen Kangtai Biological Products Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.28 0.17 0.21 0.19 0.42

Competitive Comparison of Shenzhen Kangtai Biological Products Co's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Shenzhen Kangtai Biological Products Co's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shenzhen Kangtai Biological Products Co's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shenzhen Kangtai Biological Products Co's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Shenzhen Kangtai Biological Products Co's Capex-to-Revenue falls into.



Shenzhen Kangtai Biological Products Co Capex-to-Revenue Calculation

Shenzhen Kangtai Biological Products Co's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-718.451) / 3477.439
=0.21

Shenzhen Kangtai Biological Products Co's Capex-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-188.709) / 451.659
=0.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shenzhen Kangtai Biological Products Co  (SZSE:300601) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Shenzhen Kangtai Biological Products Co Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Shenzhen Kangtai Biological Products Co's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Shenzhen Kangtai Biological Products Co (SZSE:300601) Business Description

Traded in Other Exchanges
N/A
Address
No. 6 Kefa Road, Science and Technology Industrial Park, Nanshan District, Shenzhen, CHN, 518057
Shenzhen Kangtai Biological Products Co Ltd is a human vaccine research and development company. The company is engaged in the research and development, production and sales of recombinant hepatitis B vaccine, b -type influenza Haemophilus conjugate vaccine, measles-rubella combined live attenuated vaccine, cell-free baibai broke b Haemophilus influenzae vaccine and other products.
Executives
Liu Jian Kai Directors, executives
Tao Jin Secretary Dong
Zheng Hai Fa Directors, executives
Zhou Hui Executives
Miao Xiang Directors, executives
Wen Fei Dong Director
Du Wei Min Directors, executives
Lv Zhi Yun Supervisors
Gan Jian Hui Executives
Zhu Zheng Yu Executives
Liu Qun Executives
Li Tong Executives
Yuan Li Ping Director
Li Xiang Ming Independent director

Shenzhen Kangtai Biological Products Co (SZSE:300601) Headlines

No Headlines